title: Controversies Around Epidemiology, Diagnosis and Treatment of Clostridium difficile Infection.
abstract: Clostridium difficile infection is a major public health problem. However, in recent years the epidemiology, risk factors, diagnosis, and treatment of C. difficile infection have undergone a significant change. The incidence of C. difficile has increased, not only in the healthcare sector but also in the community. Hospital-acquired infection and community-acquired disease have different risk factors, with the latter occurring in children and younger individuals without a history of antibiotic use or previous infections. From a clinician's perspective, a quick efficient diagnosis is required for patient treatment; however, the old method of using enzyme immunoassays is insensitive and not very specific. Recent literature around diagnostic testing for C. difficile infection suggests using PCR or a two-step algorithm to improve sensitivity and specificity. More failures and recurrence with metronidazole have led to treatment algorithms suggesting its use for mild infections and switching to vancomycin if there is no clinical improvement. Alternatively, if signs and symptoms suggest severe infection, then oral vancomycin is recommended as a first-line agent. The addition of a new but costly agent, fidaxomicin, has seen some disparity between the European and North American guidelines with regard to when it should be used. Lastly, rapid developments and good results with fecal microbial transplantation have also left clinicians wondering about its place in therapy. This article reviews the literature around some of the recent controversies in the field of C. difficile infection.
authors.affiliation: University of British Columbia, 2405 Wesbrook Mall, Vancouver, BC, V6T 1Z3, Canada, fawziah@mail.ubc.ca.
authors.forename: Fawziah
authors.initials: F
authors.lastname: Marra
authors.forename: Karen
authors.initials: K
authors.lastname: Ng
mesh_terms: D000617:Aminoglycosides / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D004761:Enterocolitis, Pseudomembranous / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000628:therapy; D000069467:Fecal Microbiota Transplantation / Q000009:adverse effects / Q000379:methods*; D000077732:Fidaxomicin; D006801:Humans; D015994:Incidence; D008795:Metronidazole / Q000627:therapeutic use; D025202:Molecular Diagnostic Techniques; D016133:Polymerase Chain Reaction; D019936:Probiotics / Q000627:therapeutic use*; D012008:Recurrence; D012307:Risk Factors; D014640:Vancomycin / Q000627:therapeutic use
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D008795:Metronidazole; D014640:Vancomycin; D000077732:Fidaxomicin